Molecular profiling has changed the treatment landscape in advanced non-small-cell lung cancer. Accurately identifying the tumours that harbour sensitizing EGFR mutations, the most common targetable molecular alteration, as well as those with acquired resistance mutations (e.g. T790M) on treatment is a high clinical priority. The current clinical gold standard is genotyping of tumour specimens. However, the practical utility of this approach is limited by the lack of available tissue and the potential complications associated with biopsies. With the advent of newer sequencing assays, it has become feasible to assess tumour genomics via a blood sample, termed a 'liquid biopsy'. In this review, we summarize the available techniques for liquid biopsies and their applicability for detecting sensitizing and resistance EGFR mutations and how these results may be used for making treatment decisions.
Introduction
Most advanced non-small-cell lung cancers (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). With targeted therapies, median overall survival (OS) has improved from 8-12 to 20-30 months for this patient subset [1] . Accurately identifying the tumours that harbour sensitizing EGFR mutations as well as those with acquired resistance mutations (T790M) that can be targeted by newer third-generation TKIs is a high clinical priority, with associated increases in OS of up to 46 months with personalized treatment at progression [2] . The current clinical gold-standard is genotyping of tumour biopsies. However, with the advent of newer sequencing assays, it has become feasible to assess tumour genomics via a blood sample, termed a 'liquid biopsy'. Recent data suggest that circulating tumour DNA (ctDNA), that can be used for molecular profiles, derived from NSCLC can be detected with high sensitivity in urine as well as in plasma [3] and cerebral spinal fluid [4, 5] , enabling complementary modes of tissue and liquid biopsies in this population. EGFR mutation profile by liquid biopsy is now accepted for making treatment decisions among NSCLC patients, and liquid biopsy tests have earned limited approvals in Europe, China, Japan, and the USA owing to several distinct advantages over tissue biopsy [6] .
Tissue biopsy
Lack of available tissue for performing molecular profiling, the location or size of the tumour, and the risk of complications (17% of adverse events with image guide-biopsies [7] and risk of pneumothorax requiring chest tube in up to 14% of patients [8] ), are serious limitations for performing biopsies of NSCLC tumours. In EGFR-mutant NSCLC patients with acquired resistance to EGFR TKIs, re-biopsies are feasible in only half of the patients [9] as a consequence of inaccessible tumour sites, patient refusal, or physician discretion [10] . In prospective trials, the percentage of available tissue samples for EGFR genotyping can vary greatly; even when successfully obtained, 12%-30% of samples were not sufficient for genotyping [11] [12] [13] [14] . In addition, after obtaining sufficient samples via invasive procedures, EGFR genotyping fails in 5%-10% of tests [15, 16] . Moreover, single site biopsies may not provide a representative profile of the overall predominant resistance mechanisms for a given patient [17] .
Delays in tissue biopsy often occur as a result of scheduling, specimen delivery to molecular diagnostics, and laboratory processing time. In a prospective study of EGFR genotyping in advanced lung cancer patients, the median turnaround time for tissue biopsy was 12 days for new diagnosis of NSCLC patients and 27 days for those tested for acquired resistance. In contrast, the median time was 3 days for plasma based testing using an inhouse assay for EGFR and KRAS hotspots [18] . There is also a significant difference in cost. An analysis of 8979 Medicare patients undergoing diagnostic assessment for lung cancer found that the median cost of a biopsy was $2235. However, this cost increased to a median of $14 824 if an adverse event occurred [8] . These are likely underestimates, as costs from Medicare are generally lower than from other payers. A study using simulation analytics found that a liquid-based alternative for EGFR genotyping could result in substantial financial savings [19] .
There may also be advantages to a liquid biopsy that go beyond avoiding the risks and financial costs of a tumour biopsy (Table 1) . NSCLCs are amongst the cancer types with the highest rates of point mutations, harbouring hundreds of mutations in their exome [20] , and advanced cancers are highly heterogeneous [21] . Tumour heterogeneity results from numerous genomic alterations, catastrophic events, and clonal evolution during division. Dividing cells in the tumour acquire new mutations, creating sub-clones that differ from their founder cells so that geographically separated regions in the same tumour will generally also be more genomically distinct [22] . Seeding of varying sub-clones to other organs leads to further divergent evolution. In NSCLC, multi-region whole exome sequencing studies confirm that tumours show large spatial and temporal diversity in mutational profiles [23, 24] .
A tissue biopsy may therefore only demonstrate a minority of the genetic aberrations present in the tumour, as this single site may not be representative of intra-tumour heterogeneity nor interlesional heterogeneity (Figure 1 ). Prospective analysis of EGFR mutation status in advanced NSCLC patients who underwent multiple biopsies showed frequent changes in their mechanism of acquired resistance and T790M status (40% gained or lost the mutation) [17] . This complex and dynamic quality suggests that single site biopsies may not provide a representative profile of the overall predominant resistance mechanisms for a given patient.
A study using direct DNA sequencing to detect EGFR mutations in 180 Asian patients with matched samples from primary tumour and distant sites found that nearly a fourth of those with multiple pulmonary nodules had discordant EGFR status [25] . These data suggest that re-biopsy or multiple biopsies would be advantageous, yet, as already described, this is impractical. Liquid biopsies based on ctDNA analysis are therefore effective surrogate samples for tumour molecular analysis, and also as potential dynamic markers for monitoring the efficacy of EGFR TKIs and early detection of resistance mutations [26] .
ctDNA and techniques
In 1977, the same year the eponymous Sanger sequencing method was described, Leon et al. reported elevated levels of circulating cell-free DNA (cfDNA) in the serum of cancer patients [27] . The fraction of cfDNA in serum or plasma derived from tumour cells, termed ctDNA, is hypothesized to originate from tumour secretion, necrosis, and apoptosis [28] . Circulating tumour cells (CTCs), exosomes, or platelets can also provide DNA or RNA for isolation. Plasma is preferred in the detection and characterization of ctDNA because of lower background levels of wild-type DNA [28] . The half-life of cfDNA in circulation has been estimated to be between 16 min and 2.5 h, which makes it akin to a 'real-time snapshot' of disease burden that can be monitored [28] .
ctDNA can be specifically identified in cfDNA by the presence of somatic mutations. Methods for identifying these variations range from large-scale (up to whole genome) sequencing to analysis of individual mutations using polymerase chain reaction (PCR) with specific primers, often with complementary probes for known aberrations ( Figure 2 ). The proportion of ctDNA at a specific locus is usually reported as mutant allele concentration (copies/ml) or mutant allele fraction (%). ctDNA often represents <1% of cfDNA in a sample and, consequently, reliable detection across cases requires sensitive analysis methods [29] . The sensitivity of sequencing is technically limited by the error rate of DNA polymerase, often considered to be in the range of 0.01% [30] . An additional limitation on detection of rare alleles results from Poisson sampling statistics, whereby an allele that is present at a very low fraction may not be present in a given blood sample. Therefore, it has been suggested that individual mutations present in ctDNA at levels <0.01% mutant allele fraction would be undetectable [31] . The sensitivity of classical Sanger (chain-termination) method to detect variant alleles is >10% [29] , inadequate for wide clinical use where ctDNA levels can be far lower. In 1999, Kenneth Kinzler and Bert Vogelstein described digital PCR (dPCR) to identify rare cancer mutations [32] (Figure 2A1 ). The most common application of dPCR now relies on generating thousands to millions of water droplets in an oil emulsion rather than physically separated chambers, and is termed droplet dPCR (ddPCR), first exemplified by the same group in a technique called BEAMing (beads, emulsion, amplification, and magnetics) [33] . Both dPCR and ddPCR have a rapid turnaround time and are useful in detecting and quantifying recurrent hot-spot mutations or resistance mutations, and can, in principle, achieve a best-demonstrated detection below 0.001% [34] . In practice, the sensitivity will be limited by the amount of cfDNA analysed, which varies per patient and disease state from a few thousand to hundreds of thousands of copies, with a median around 15 000 amplifiable copies per 10 ml blood sample [35] .
Methods that use next-generation sequencing (NGS), and generate sequencing libraries across selected regions of the genome, are commonly referred to as 'targeted sequencing' ( Figure 2B ). Forshew et al. described the first implementation of targeted sequencing to detect rare cancer mutations in ctDNA. Using a two-step amplification process to generate tagged (barcoded) amplicons, they were able to identify mutations across a gene panel at allele fractions as low as 2% in plasma, with sensitivity and specificity >97% [36] . This method, termed TAm-Seq (for Tagged-Amplicon Sequencing), could also identify predefined individual mutations (e.g. hot-spot mutations or previously characterized patient-specific alterations) at allele fractions as low as 0.14%. An enhanced version of TAm-Seq, eTAm-Seq, was developed to identify mutations in hot-spots (including EGFR) and entire exons across a gene panel, and an assay covering a panel of 35 genes was described in 2016, with detection of mutations at allele fractions of 0.06%-0.08% at nearly 40% sensitivity, and sensitivity of 90% for mutations present at allele fractions of 0.25% and greater [35] .
Alternative methods use hybrid capture-based deep sequencing, such as the Guardant360 assay, which covers regions in 70 genes (including the actionable EGFR mutations), and uses a library of individually tagged cfDNA molecules to reduce false positives [37] . In a study utilizing the Guardant360 assay to profile ctDNA from patients with different cancer types, a subset with matched tissue tests were compared with results from the tissue sequencing project, TCGA, and high levels of accuracy were observed when blood and tumour were collected within 6 months of each other [38] . This demonstrates the potential of NGS technologies. Wider-scale analysis such as whole-exome sequencing ( Figure 2C ) and shallow whole-genome sequencing can be carried out to detect de novo mutations and chromosomal aberrations and study clonal evolution when the ratio of ctDNA to cfDNA is relatively high (5% or greater) [39, 40] . It is likely that future ctDNA studies will rely on both ultrasensitive targeted detection methods as well as wider-scale analysis at different stages of diagnosis, monitoring, and treatment.
NGS-based methods allow for de novo sequencing of key regions in EGFR to identify mutations at low allele fractions. While these are now emerging as practical tools, the most widely used clinical tests have used PCR-based technologies to detect mutations in EGFR hot spots. Kits approved or endorsed by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have employed the Scorpion Amplification Refractory Mutation System (SARMS) ( Figure  2A2 ). Clinical assays include the Cobas EGFR assay, which can detect mutations in exons 18, 19, 20 , and 21 with at least 25-100 copies of the mutation per millilitres [41] . The therascreen SARMS kit has a median limit of detection of 1.42% [42] . Figure 1 . Liquid biopsy for discovery of actionable EGFR mutations, monitoring response to therapy, and detecting development of TKI resistance. Liquid biopsy carried out at diagnosis guides treatment with a TKI to target actionable mutations (A). ctDNA levels can correlate to response to TKIs (B). At progression, as ctDNA levels rise, one would ideally obtain a repeat tissue biopsy to guide next treatment decision (C). However, even when a tissue biopsy is carried out, due to tumour heterogeneity, it may miss mutations due to sampling bias (D).
The peptide nucleic acid-locked nucleic acid (PNA-LNA) clamp method exploits the tighter binding affinity of PNA and LNA probes to DNA sequences rather than to the DNA duplex, which prevents amplification of wild-type alleles, and has been employed in EGFR detection [43] . The commercially available PNAClamp technology has a stated limit of detection of <1% for EGFR mutations [44] . A range of other methods have been developed for detection of EGFR mutations at low allele fractions. A method that uses multiplex PCR amplification and detection based on mass spectroscopy can achieve detection of key hot-spot variants with as low as 0.1% minor allele frequency [45] . These alternative methods have been utilized in studies of EGFR mutations, but to the best of our knowledge have so far not been widely used.
Clinical use Detection of activating EGFR mutations to guide initial treatment with TKIs
The first trial to perform a pairwise comparison of tissue and liquid biopsy for EGFR mutations was conducted as part of a phase II study of 27 Japanese NSCLC patients in 2006 [46] ( Table 2 ). When direct sequencing was used, serum EGFR mutational status was not correlated with response to gefitinib, but when SARMS was used to detect serum EGFR mutation there was a statistical correlation with treatment response. Direct sequencing, therefore, seemed unsatisfactory for detection of EGFR mutations in serum. In pairs of tumour and serum samples (n ¼ 11), the EGFR mutation status in the tumours was consistent with those in the serum in 72.7% of the paired samples by SARMS. The following year, the same group tested 42 patients, and found an even higher concordance rate of 92.9%. They reported a strong correlation between either tissue or serum EGFR mutation status and response to gefitinib as well as progression-free survival (PFS) [47] .
Two large multinational trials, IGNITE and ASSESS, have studied the efficacy of EGFR mutation testing in the real-world setting [48] . In the IGNITE trial, 3382 patients were enrolled and plasma and tissue data were available for 2581 patients. The techniques used for EGFR testing were not centralized and had limited sensitivity. The plasma sensitivity for detection of tissueconfirmed EGFR mutations was <50%. The ASSESS trial had data available from 1162 matched tissue and plasma samples and found a concordance rate of 89.1%, with a sensitivity for detecting mutations in plasma of 46% and specificity of 97.4% [49] . The low sensitivity suggests that wide implementation requires optimization, standardization, and validation. In fact, the study found large variation in the sensitivity of plasma testing amongst Targeted sequencing allows one to focus on specific regions of interest or alternatively, perform whole exome sequencing. Two main approaches to targeted sequencing include (B1) amplicon-based, using PCR amplification with primers for selected regions to generate targeted sequencing libraries; or (B2) ligationbased library preparation, followed by enrichment for targeted regions using hybridization to sequence baits (hybrid-capture). (C) Whole genome sequencing does not require a priori knowledge of genetic mutations and can be useful if ctDNA levels are high.
countries, from 36% to 100%. In subgroup analysis of only therascreen (an SARMS-based assay), the concordance rate was 95%, sensitivity increased to 73% and the specificity was 99% with a NPV of 95%. Similarly, subgroup analysis looking at Cobas EGFR testing alone found a 96% concordance rate, 75% sensitivity, 100% specificity, and NPV of 95% [50] .
A meta-analysis examining 27 studies conducted between the years 2007 and 2015, including over 4000 patients, generated a receiver operating characteristic (ROC) curve, and found the area under the curve (AUC) to be 0.92, demonstrating high diagnostic accuracy (AUC > 0.9), with positive likelihood ratio >10. They found a pooled sensitivity of 64% for detection of the EGFR exon 19 deletions and 57% for L858R substitution mutations with 99% specificity for both [51] . As Oxnard et al. point out, in the context of a relatively uncommon mutation, specificity is more important than sensitivity. A sacrifice in test sensitivity with an accompanying small increase in specificity results in a dramatic increase in positive predictive value. They give the example that to detect an EGFR mutation present in 8.6% of patients, with a 10% decrease in sensitivity from 80% to 70%, if the specificity of 95% increased to 99% then the PPV would more than double, from 43% to 87% [52] . Two separate meta-analyses have found very similar results for pooled specificity (>93%), pooled sensitivity (>60%), and AUC (0.93 and 0.91) for EGFR analysis by ctDNA. These authors also concluded that the high diagnostic accuracy of ctDNA makes it a suitable screening test for EGFR mutations [53, 54] .
The phase III IPASS trial, comparing gefitinib to carboplatinpaclitaxel amongst 233 Japanese patients with advanced NSCLC, retrospectively reported EGFR mutations in ctDNA detected by SARMS in 23.7% of patients versus 61% from tumour samples [55] . There was an unacceptably high false negative rate of 56.9%, which may be attributed to the use of serum rather than plasma, DNA extraction techniques, and a less refined SARMS kit. Another study of 54 patients with known clinical response to gefitinib or erlotinib found that only 47% of EGFR mutations were detected when an SARMS-based technique was used [56] . A similar study using SARMS detected only 39% of EGFR mutations in plasma ctDNA from 18 patients with known EGFR mutations [57] . These mixed results from earlier studies highlighted the challenges of ctDNA analysis, but also its great potential. With more data on pre-analytical variables and improvements in sample collection processes, alongside more robust, and sensitive methods for mutation detection, more recent studies have shown consistently greater sensitivity for ctDNA detection in a range of clinical applications [28] .
In a first application of dPCR for analysis of EGFR in peripheral blood samples from NSCLC patients, Yung et al. developed probes to detect the exon Del19 and L858R at exon 21, which account for >85% of all clinically relevant EGFR mutations [58] . Their study of 35 patients reported a sensitivity of 92% and a perfect specificity [59] . More recently, Sacher et al. prospectively validated a ddPCR technique in a study of 180 patients to detect EGFR mutations at diagnosis or relapse. They reported that ddPCR for plasma genotyping of sensitizing EGFR mutations also had 100% specificity and positive predictive value given no false positives, and a sensitivity of 69%-80% [18] .
The phase III EURTAC trial, comparing upfront erlotinib to platinum-based chemotherapy in 173 EGFR-mutant NSCLC patients, assessed the feasibility for testing EGFR mutations in a liquid biopsy by real-time PCR TaqMan assay as a surrogate of tissue testing, and compared outcomes according to detection of mutation in tissue versus liquid biopsy [60] . This study demonstrated that tumour and peripheral EGFR mutation status had [47, 62, 60] EGFR mutation status correlates to TKI response, PFS, as well as OS. [55, 56, 57] Early studies showed mixed results in detecting EGFR ctDNA. [58, 59, 61] Improved methodology has greatly improved sensitivity and specificity of testing. [48, 49, 50] Results from two large multi-national trials suggest that optimization, validation, and standardization are needed to improve performance. [51, 53, 54] Meta-analyses show high diagnostic accuracy of ctDNA for EGFR mutation testing. ctDNA as a marker of efficacy [52, 71, 72] ctDNA levels may predict progression before clinical progression. [61, 68, 69] Clearance of ctDNA may predict response and prognosis. Identifying resistance mutations in patients progressing on TKI [74, 75, 76] Detection of the T790M mutation can be accurately carried out via liquid biopsy, and the presence of any detectable T790M ctDNA may be clinically relevant. [24, 73, 74] T790M status by liquid biopsy correlates well to response to third-generation TKIs.
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; ctDNA, circulating tumor DNA.
similar ability to predict OS and PFS [60] . Similarly, to prospectively validate the use of blood-based EGFR testing, Mok et al. demonstrated high performance characteristics of the Cobas EGFR Blood test [61] . The phase III FASTACT-2 trial randomized advanced NSCLC patients to platinum-gemcitabine firstline chemotherapy intercalated with either erlotinib or placebo followed by maintenance treatment with erlotinib or placebo. Cobas EGFR testing had a high tissue-blood concordance of 88% with a sensitivity of 75%, specificity of 96%, and PPV of 94% [61] . The phase IV IFUM trial assessed the efficacy of gefitinib in Caucasian NSCLC patients and the clinical utility of the therascreen EGFR RGQ PCR kit for plasma ctDNA was tested. Concordance in mutation status amongst 652 matched samples was 94.3%, sensitivity was 65.7%, and specificity was 99.8%. The trial reported that patients' outcome was similar independent of EGFR mutation being detected in plasma or in tissue [response rate (RR) 69.8% versus 76.9%, and PFS, 10.2 versus 9.7 months]. Of significance, 12 patients without available tissue samples for genotyping were discovered to have EGFR mutations via plasma testing [62] .
In January 2015, the EMA granted marketing approval to the therascreen assay. Given the 34% false negative rate in the IFUM trial, they specified that the test should only be used for patients without a tumour sample. In June 2016, the Cobas EGFR mutation test v2 was approved by the FDA for the detection of exon 19 deletions and the L858 substitution mutation in plasma. In September 2016, this was extended to cover also the T790M resistance mutation. Given that a relatively low number, 76.7% of patients, who had a detectable EGFR mutation by tissue biopsy also had a detectable mutation in plasma, the FDA specified that those with negative plasma testing should be retested with tissue sampling.
Recently, NGS-based ctDNA assays have been introduced as an important tool for molecular profiling in untreated NSCLC patients [63] , detecting clinically relevant and actionable mutations in up to 23% of patients when tissue was unavailable, and also in previously treated NSCLC patients [64, 65] . The assay used, sensitivity of the test, and sample collection time point should be kept in mind when interpreting concordance between plasma and tumour analyses [65] . Indeed, liquid biopsies can be used longitudinally as a non-invasive approach to monitor patient treatment outcome and may provide a surrogate for response evaluation by radiographic RECIST assessment [63] . Also, recently ctDNA has been demonstrated as an important tool for detecting the emergence of resistance mutations on treatment [26, 66, 67] . Further analysis in well-defined patient populations is underway to provide supporting data for the clinical utility of such assays.
ctDNA as a dynamic marker of efficacy and for the identification of resistance mutations in patients relapsing on targeted therapies ctDNA levels may predict progression before standard imaging progression by RECIST. The first study to demonstrate this in NSCLC found that serial plasma genotyping could detect resistance up to 16 weeks before radiographic progression [52] . Analysis of the FASTACT-2 data found that at cycle three, if a cfDNA sample was EGFR mutant positive, RR was only 33% compared with 66% for those who cleared their EGFR mutation positivity [61] . In a study of 81 patients with NSCLC treated with an EGFR-directed TKI therapy, PFS was 6.3 months for those with detectable levels after 2 months of treatment compared with 10.1 months for those without [68] . Similarly, in a study of 62 patients with EGFR mutated NSCLC, failure to clear plasma EGFR mutated ctDNA after 10 weeks of therapy was a predictor of lower PFS and OS [69] . A prospective cohort of 42 patients similarly demonstrated that ctDNA levels may be a predictive biomarker: EGFR mutant allele fractions provided early prediction of clinical response and significantly correlated with tumour shrinkage at 2 months [70] .
The T790M mutation is the main mechanism of resistance in half of EGFR-mutant NSCLC patients treated with first-or second-generation EGFR TKIs. In a study of 117 patients who had acquired resistance to TKI therapy, nearly half of patients who were T790M positive by plasma ctDNA were identified at a median of 2.2 months before clinically progressive disease [71] . In an unselected cohort of 199 patients with NSCLC, monitoring for EGFR mutations allowed for the detection of the T790M acquired mutation as early as 344 days before clinical disease progression [72] . The hypothesis that switching treatment based on detection of resistance mutations in ctDNA instead of on RECIST radiographic criteria would have a positive impact on patient outcomes requires further evaluation. The ongoing randomized phase II APPLE trial aims to validate this hypothesis [73] .
The identification of the acquired resistance T790M mutation triggered development of third generation EGFR TKIs that can overcome this mechanism of resistance. Indeed, this acquired EGFR mutation may also be detected in plasma [74, 75] . Jenkins et al. reported a 61% sensitivity for the Cobas plasma test in patients that were T790M-positive in a tissue sample; the authors recommended that in clinical practice, patients with a negative screening plasma test should undergo tissue biopsy testing if feasible [75] . The phase I/II TIGER-X study assessed the efficacy of the third-generation EGFR TKI, rociletinib, in previously treated EGFR-mutant advanced NSCLC patients [76] . Among 548 assessable patients, plasma testing was carried out by therascreen in tissue, BEAMing in plasma, and footprint mutation enrichment NGS in urine. In a retrospective analysis, they found that response rates were comparable regardless of sample type used (33.9% for tissue versus 32.1% for plasma versus 36.7% for urine). Duration of response and PFS were also comparable.
When using tissue as a reference (N ¼ 60), the sensitivity of urine or plasma testing for T790M, L858R, and Del19 mutations was: 72% for urine compared to tissue vs. 93% for plasma compared to tissue, 75% vs. 80%, and 67% vs. 80%, for the three EGFR mutations respectively; and the combination of urine and plasma testing improved sensitivity compared with either strategy alone [3] . Furthermore, the combination of urine and plasma testing detected more T790M mutations than tissue testing alone (92% versus 83%). Those with T790M detected by ctDNA (with or without tissue confirmation) had a demonstrable response, showing that the plasma or urine test was a true positive [3] .
Efficacy of osimertinib according to T790M positivity in liquid biopsy by BEAMing was presented in a retrospective analysis, with a 30% false negative rate of plasma genotyping [74] .
Prospective validation of osimertinib efficacy according to T790M positivity in a blood biopsy has been recently reported, and it confirms the retrospective data. Patient populations in whom T790M was detected in plasma had similar responses to osimertinib to patients when T790M was detected in tissue [26, 74] . Recent work suggests that at the time of clinically overt resistance, the simple presence of any detectable level of T790M in itself is clinically relevant, even with mutant allele fractions as low as 0.1% [26] . It is unknown whether some molecular alterations detected by ultrasensitive NGS methods represent clinically irrelevant sub-clones, especially those with an MAF of 0.01%-0.1% [77] . Additional studies are needed to confirm the minimum biological threshold with clinical relevance to guide treatment decisions.
ctDNA testing has also allowed ongoing genomic analysis for patients on third generation EGFR inhibitors. With serial monitoring of patients on osimertinib, Thress et al. identified a novel tertiary EGFR resistance mutation, C797S, which prevents drug binding. In this manner, the resistance mechanism was recognized before the new drug was even approved [78] . While the T790M and C797S mutations in EGFR have been identified as key drivers of resistance, for the majority of patients the eventual progression will be driven by mechanisms outside of these hotspot mutations in EGFR. The role of NGS-based liquid biopsy analysis is becoming increasingly important in discovering new mechanisms and in clinical assessment of patients to identify resistance to EGFR-targeted TKI.
Some studies have reported that the ability to detect ctDNA varies by extent of disease [18, 79, 80] . These results suggest that one may be able to select a subset of patients where plasma ctDNA testing alone may obviate the need for tissue or other complementary testing methods. As in first-line treatment, clearance of plasma EGFR mutation after 6 weeks on osimertinib appears to be associated with improved outcome in T790M positive NSCLC patients, endorsing the dynamic predictive value of ctDNA on treatment [81] .
The use of alternate methods, such as collected CTCs when combined with ctDNA, may also improve detection. In an exploratory analysis of 40 patients with EGFR-mutated tumours who progressed on TKI therapy, the use of ctDNA genotyping missed 30% of cases with tissue-identified T790M. However, when combined with genotyping from simultaneously collected CTCs, the two assays together identified all patients with this mutation. Additionally, the T790M mutation was identified in 35% of patients with a negative or indeterminate tissue biopsy when CTC and ctDNA analysis was combined [11] .
Discussion Conclusion
With the advent of newer ctDNA detection platforms, it is likely that sensitivity can be optimized with standardization and improved techniques. The relatively low sensitivity reported in some studies can likely be attributed to lack of consensus on choice of sample, storage, and technical approaches. Standardization should include the use of plasma over serum, avoidance of heparinized tubes, early centrifugation of tubes, and standardization of cell free extraction methods [28] . The comparative ease of ctDNA sample collection has accelerated clinical decision-making, as well as translational research, such as the identification of the novel acquired EGFR C797S mutation, exemplifying the power of ctDNA to track clonal evolution and tailor treatment. Identification of new mechanisms of acquired resistance in ctDNA in a dynamic manner may help to develop new personalized treatments among EGFR-mutant NSCLC patients. Liquid biopsies may be considered the new standard tool for detecting acquired resistance mutations, with tissue biopsies recommended only in cases without identifiable ctDNA. Following initial approvals by regulatory authorities, plasmabased testing for EGFR mutations is now entering clinical use. With improvements in methods and assays, it is likely that, in the near future, a subset of patients with advanced disease may only require plasma ctDNA testing, possibly with the addition of CTC or urine ctDNA testing, thus avoiding the need for percutaneous biopsy. 
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